LIPI-PROTECT-1 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP1) (LPP1)
Effect of the Dietary Supplement LIPI-PROTECT-1 on Plasma LDL Cholesterol Concentration in Subjects With Moderate Hypercholesterolemia: A Pilot Study.
This is a multicenter, uncontrolled pilot study evaluating changes in plasma LDL-cholesterol (LDL-C) concentrations before and after 3 months of intake of the dietary supplement LIPI-PROTECT-1.
The main objective of this clinical trial is to evaluate the effect of LIPI-PROTECT-1 on plasma LDL-C concentration after 3 months of supplementation in participants with untreated moderate hypercholesterolemia.
A mean reduction in plasma LDL-C levels of approximately 14% (0.20 g/L) is expected after 3 months of supplementation.
The primary endpoint is the absolute (g/L) and relative (%) change in plasma LDL-C concentration between baseline and Month 3.
研究概览
详细说明
Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for coronary cardiovascular disease. In individuals at low cardiovascular risk, lifestyle and dietary measures are recommended to reduce LDL-C levels and/or overall cardiovascular risk. Dietary supplements may be considered as part of these measures when their efficacy has been demonstrated.
LIPI-PROTECT-1 is a dietary supplement containing plant extracts and vitamins that may contribute to reducing plasma LDL-C levels. Some of its individual active ingredients have previously been investigated in clinical studies and have shown an LDL-C-lowering effect. However, the combination of these active ingredients has not previously been evaluated in a clinical study.
This pilot, multicenter, uncontrolled study is designed to provide preliminary estimates of the effect of LIPI-PROTECT-1 in adults with untreated moderate hypercholesterolemia.
A total of 20 men and women aged 18 to 65 years with untreated moderate hypercholesterolemia will be included. Participants will have an LDL-C level ≥1.5 g/L and a low cardiovascular risk. They will consume LIPI-PROTECT-1 for 3 months and will be required to maintain stable body weight, dietary habits, and physical activity throughout the study.
The primary objective is to assess the effect of LIPI-PROTECT-1 on plasma LDL-C concentration after 3 months of supplementation. The primary outcome will be the absolute and relative change in LDL-C concentration between baseline and Month 3. A mean reduction of approximately 14% (0.20 g/L) in LDL-C is expected after 3 months of supplementation.
Secondary objectives are to evaluate the effect of LIPI-PROTECT-1 after 1 and 3 months compared with baseline on body weight, body mass index, waist circumference, systolic and diastolic blood pressure, resting heart rate, fasting glucose, LDL-C, non-HDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, LDL-C/HDL-C and total cholesterol/HDL-C ratios, and the atherogenic index (non-HDL-C/HDL-C).
Safety will also be assessed by comparing selected laboratory parameters between baseline and Month 3, including AST, ALT, gamma-glutamyl transferase, creatine kinase, lactate dehydrogenase, bilirubin, creatinine, and urea. Adherence to the dietary supplement will be assessed throughout the study.
Participants with high or very high cardiovascular risk, lipid-lowering treatment, diabetes, severe chronic diseases, or concomitant treatments likely to interfere with the assessment of efficacy or safety will be excluded.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Nord
-
Lille、Nord、法国、59019
- Prevention research center - Institut Pasteur de Lille
-
-
Vaucluse
-
Avignon、Vaucluse、法国、84140
- Biophysium
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Men and women aged 18-65 years
For women :
If pre-menopausal: effective non-estrogenic* contraception initiated at least 2 cycles prior and maintained throughout the study If post-menopausal: not receiving estrogenic* Hormone Replacement Therapy (HRT)
- LDL-cholesterol ≥ 1.5 g/L (calculated using the Friedewald formula)
- Aware of their hypercholesterolemia and previously informed about the associated lifestyle and dietary measures
- BMI between 20 and 35 kg/m² (inclusive)
- Stable weight, dietary habits, and physical activity level for at least 3 months prior to the start of the study, with agreement to maintain them throughout the study
- Willing to comply with study requirements
- Signed informed consent
Exclusion Criteria:
- Subjects receiving lipid-lowering or anti-dyslipidemic therapy (statins, ezetimibe, cholestyramine, fibrates, etc.)
- Subjects with triglyceride levels > 4 g/L
- Subjects requiring immediate lipid-lowering therapy
- Subjects with diabetes (whether treated with medication or not, or diagnosed during the initial visit based on fasting blood glucose > 1.26 g/L)
- Subjects receiving beta-blockers and/or diuretics
- Subjects at high or very high cardiovascular risk according to ESC/EAS 2025 guidelines (assessed using the SCORE2 score, Appendix 2)
- Subjects receiving anticoagulant therapy
- Subjects receiving antiretroviral therapy
- Subjects requiring immediate dietary intervention, or exhibiting fluctuating eating habits or an eating disorder (anorexia, bulimia, binge eating disorder)
- Subjects on unstable treatment (initiated less than three months prior) or requiring the initiation of treatment during the study that, in the investigator's opinion, could interfere with the assessment of study endpoints (efficacy parameters: LDL, TG, HDL, blood glucose, blood pressure, weight; safety parameters: markers of hepatic, muscular, or renal function) Subjects who have consumed dietary supplements or functional foods capable of affecting cholesterol or triglyceride levels (phytosterols, phytostanols, red yeast rice, policosanols, beta-glucans at doses exceeding 3 g/day, artichoke or garlic extracts, probiotics, etc.) within the last 6 weeks
- Subjects suffering from a severe chronic condition deemed incompatible with participation in the study by the investigator (serious digestive disorders, renal insufficiency, coronary artery disease, immunodeficiency, heart failure, rhythm disorders, active malignancy, hematological disease)
- Subjects with an allergy to any of the components of LIPI-PROTECT-1
- Pregnant or breastfeeding women, or women intending to become pregnant within the next 4 months
- Subjects under legal protection (guardianship/curatorship, deprivation of liberty) or not covered by a social security scheme
- Subjects participating in another clinical study or currently within the exclusion period of another study
- Subjects whose condition is judged by the principal investigator or a qualified co-investigator deems that their health status or concomitant treatments are incompatible with the proper conduct of the clinical study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Food supplement group
Three tablets of LIPI-PROTECT-1 per day (1 at the end or after breakfast and 2 during dinner). Food supplements are consumed during 3 months by healthy volunteers |
All subjects will consume 3 tablets per day during the entire intervention period, i.e. 12 weeks between V0 and V3, distributed as follows: 1 tablet in the morning at the end of or after breakfast (no taking on an empty stomach) and 2 tablets in the evening during dinner. If a dose is missed, 1 tablet can be taken at the next dose |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To evaluate the effect of LIPI-PROTECT-1 on plasma LDL-cholesterol concentration (absolute value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia
大体时间:To baseline at 3 months
|
To evaluate the absolute (g/L) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3). |
To baseline at 3 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To evaluate the effect of LIPI-PROTECT-1 on plasma LDL-cholesterol concentration (relative value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia.
大体时间:To baseline at 3 months
|
To evaluate the relative (%) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3). |
To baseline at 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on LDL cholesterol.
大体时间:At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in LDL cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on Non HDL cholesterol.
大体时间:At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in Non HDL cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on total cholesterol.
大体时间:At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in total cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on HDL cholesterol.
大体时间:At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in HDL cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on triglycerides.
大体时间:At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on triglycerides in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on non HDL cholesterol/LDL (atherogenic index).
大体时间:At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non HDL cholesterol/LDL (atherogenic index) (ratio). |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on ratio LDL/HDL.
大体时间:At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non ratio LDL/HDL (ratio). |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on ratio total cholesterol/HDL.
大体时间:At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on ratio total cholesterol/HDL (ratio). |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on fasting blood glucose levels.
大体时间:At baseline, 1 month and 3 months
|
Variation in fasting blood glucose (unit: g/l) between VS, V1, and V3 |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on weight.
大体时间:At baseline, 1 month and 3 months
|
Changes in weight (unit : kilograms) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on Body Mass Index (BMI).
大体时间:At baseline, 1 month and 3 months
|
Changes in BMI (weight and height will be combined to report BMI) in kg/m^2between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on waist circumference.
大体时间:At baseline, 1 month and 3 months
|
Changes in waist circumference (unit: cm) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on arterial blood pressure
大体时间:At baseline, 1 month and 3 months
|
Variation in systolic blood pressure and diastolic blood pressure (unit: mm Hg) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-1 on heart rate
大体时间:At baseline, 1 month and 3 months
|
Variation in Heart rate (unit: Pul/min) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-1 on hepatic metabolism: ASAT/ALAT, GGT
大体时间:At baseline, 1 month and 3 months
|
Changes in safety biomarkers : ASAT/ALAT and GGT(unit: UI/l) between baseline and V3 . |
At baseline, 1 month and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-1 on hepatic metabolism : Creatinine, bilirubin
大体时间:At baseline and 3 months
|
Changes in safety biomarkers : Creatinine, bilirubin (unit: mg/dl) between baseline and V3. |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-1 on renal metabolism : Urea
大体时间:At baseline and 3 months
|
Changes in safety biomarkers : Urea (unit: mg/dl) between baseline and V3. |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-1 on renal metabolism : Creatinine Phophoskinase (CPK)
大体时间:At baseline and 3 months
|
Changes in safety biomarkers : CPK (unit : UI/l) between baseline and V3. |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-1 on Renal metabolism : Lactate Deshydrogenase (LDH)
大体时间:At baseline and 3 months
|
Changes in safety biomarkers : LDH (unit : UI/l) between baseline and V3. |
At baseline and 3 months
|
|
To assess adherence to LIPI-PROTECT-1 consumption by pillbox weighing
大体时间:At baseline, 1 month and 3 months
|
Adherence assessed by weighing the pillbox at each visit and comparing the weight with the initial weight recorded at baseline (V0). |
At baseline, 1 month and 3 months
|
|
To assess self-reported adherence to LIPI-PROTECT-1 consumption
大体时间:At 1 month, 2 months and 3 months
|
Adherence assessed through participant self-reporting of supplement consumption and missed doses. |
At 1 month, 2 months and 3 months
|
|
To assess adherence to LIPI-PROTECT-1 consumption by counting returned tablets
大体时间:At 3 months
|
Adherence assessed by counting the remaining tablets returned by participants at the end of the study. |
At 3 months
|
合作者和调查者
调查人员
- 学习椅:Coralie Berthier, PhD、Institut Pasteur de Lille
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2026-A00450-51
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.